Research Progress on Acupuncture in Improving the Fever Symptom of Patients with Osteoporosis after Intravenous Infusion of Zoledronic Acid

随着社会经济及生活水平的改善，我国人口老龄化逐渐加剧，老年人骨质疏松症也已成为现阶段影响人类健康的主要公共卫生问题之一。密固达是新一代的双膦酸盐制剂，是临床上治疗骨质疏松症的一线药物。然而，骨质疏松症患者静脉注射密固达后发热是患者的主要不良反应，而通过针灸方法改善该症状，以提高骨质疏松症患者使用密固达的依从性及舒适性。然而，针灸改善静脉滴注密固达后发热的作用机制目前尚未明确，尚无对其机制研究的统一定论，针灸治疗热病呈现多靶点。本文主要综述针灸治疗方法在改善骨质疏松症患者在静脉滴注密固达后发热的研究进展，并为密固达的临床应用提供依据，以减少其发热的症状，减少患者痛苦，提高患者的依从性。With the improvement of social economy and living standards, the aging of the population in China is gradually intensifying, and osteoporosis in the elderly has become one of the major public health problems affecting human health at the present stage. Aclasta is a new generation of bisphosphonate preparation and a first-line drug for the clinical treatment of osteoporosis. However, fever after intravenous injection of Aclasta in patients with osteoporosis is the main adverse reaction. Acupuncture can be used to improve this symptom, so as to enhance the compliance and comfort of patients with osteoporosis using Aclasta. However, the mechanism of acupuncture in improving the fever after intravenous infusion of Aclasta is still unclear, and there is no unified conclusion on the research of its mechanism. Acupuncture treatment for febrile diseases presents multiple targets. This article mainly reviews the research progress of acupuncture treatment methods in improving the fever of patients with osteoporosis after intravenous infusion of Aclasta, and provides a basis for the clinical application of Aclasta, aiming to reduce its fever symptoms, alleviate patients' pain, and improve patients’ compliance.